CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Immunotherapy of cytomegalovirus infection by low-dose adoptive transfer of antiviral CD8 T cells relies on substantial post-transfer expansion of central memory cells but not effector-memory cells.
Immunotherapy of cytomegalovirus infection by low-dose adoptive transfer of antiviral CD8 T cells relies on substantial post-transfer expansion of central memory cells but not effector-memory cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
巨细胞病毒(CMV)在复制上具有宿主物种特异性。所有CMV的一个标志性特征是,在免疫功能正常的宿主体内,生产性原发感染受到固有免疫和适应性免疫应答的协同控制。
因此,感染通常无明显临床症状,并发展为潜伏感染,称为“潜伏”。在潜伏期间,病毒维持在不复制的状态,当免疫监视减弱时可重新激活为生产性感染。相比之下,感染免疫功能受损的宿主会导致CMV疾病,表现为病毒性多器官组织病理学改变,最终导致器官衰竭。造血细胞移植(HCT)受者在治疗性血液消融性白血病治疗与免疫系统重建之间的“风险窗口期”发生原发或再激活CMV感染,仍是一项临床挑战。在小鼠实验性HCT及鼠CMV(mCMV)感染模型中的研究,随后在HCT患者中人CMV(hCMV)再激活的临床试验,揭示了病毒特异性CD8 T细胞在过继性细胞转移(AT)中的保护功能。来自潜伏感染宿主的记忆CD8 T细胞是AT免疫治疗的首选来源。令人惊讶的是,极少量的这些细胞即可预防CMV疾病,提示少数转移细胞具有即时效应功能,或克隆扩增产生了大量效应细胞。在小鼠模型中,记忆细胞群由静息性中央记忆T细胞(TCM)、常规效应记忆T细胞(cTEM)和膨胀性效应记忆T细胞(iTEM)组成。iTEM在潜伏感染宿主中随时间数量增加,这一现象被称为“记忆膨胀”(MI)。
因此,它们看似是免疫治疗中一个有前景的来源。然而,我们在此表明,iTEM对AT后感染控制贡献甚微,后者几乎完全依赖于TCM优越的增殖潜能。
Cytomegaloviruses (CMVs) are host species-specific in their replication. It is a hallmark of all CMVs that productive primary infection is controlled by concerted innate and adaptive immune responses in the immunocompetent host. As a result, the infection usually passes without overt clinical symptoms and develops into latent infection, referred to as "latency". During latency, the virus is maintained in a non-replicative state from which it can reactivate to productive infection under conditions of waning immune surveillance. In contrast, infection of an immunocompromised host causes CMV disease with viral multiple-organ histopathology resulting in organ failure. Primary or reactivated CMV infection of hematopoietic cell transplantation (HCT) recipients in a "window of risk" between therapeutic hemato-ablative leukemia therapy and immune system reconstitution remains a clinical challenge.
Studies in the mouse model of experimental HCT and infection with murine CMV (mCMV), followed by clinical trials in HCT patients with human CMV (hCMV) reactivation, have revealed a protective function of virus-specific CD8 T cells upon adoptive cell transfer (AT). Memory CD8 T cells derived from latently infected hosts are a favored source for immunotherapy by AT. Strikingly low numbers of these cells were found to prevent CMV disease, suggesting either an immediate effector function of few transferred cells or a clonal expansion generating high numbers of effector cells.
In the murine model, the memory population consists of resting central memory T cells (TCM), as well as of conventional effector-memory T cells (cTEM) and inflationary effector-memory T cells (iTEM). iTEM increase in numbers over time in the latently infected host, a phenomenon known as 'memory inflation' (MI). They thus appeared to be a promising source for use in immunotherapy.
However, we show here that iTEM contribute little to the control of infection after AT, which relies almost entirely on superior proliferative potential of TCM.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。